Kelly Dooley (Johns Hopkins University, USA) and Gavin Churchyard (Aurum Institute, South Africa) discuss their trial on tuberculosis prevention in people with HIV taking dolutegravir-based antiretroviral therapy with Deputy Editor Philippa Harris.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv